Inhibition of DNA Topoisomerase Type II<i>α</i>(TOP2A) by Mitoxantrone and Its Halogenated Derivatives: A Combined Density Functional and Molecular Docking Study

Saleh, Abu; Solayman, Md.; Hoque, Mohammad Mazharol; Khan, Mohammad A. K.; Sarwar, Mohammed G.; Halim, Mohammad A.

doi:10.1155/2016/6817502

Cited by 22 publications

(13 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TOP2A is a widely used target of existing anti-cancer drugs and it's expression is often used as a cancer cell marker because of it's role in cell proliferation [ 61 ]. Indeed, it is the only protein identified in our dataset that is targeted by currently FDA approved drugs for PCa.…”

Section: Discussionmentioning

confidence: 99%

Probing the prostate tumour microenvironment II: Impact of hypoxia on a cell model of prostate cancer progression

Tonry

Armstrong

2017

Oncotarget

View full text Add to dashboard Cite

Approximately one in six men are diagnosed with Prostate Cancer every year in the Western world. Although it can be well managed and non-life threatening in the early stages, over time many patients cease to respond to treatment and develop castrate resistant prostate cancer (CRPC). CRPC represents a clinically challenging and lethal form of prostate cancer. Progression of CRPC is, in part, driven by the ability of cancer cells to alter their metabolic profile during the course of tumourgenesis and metastasis so that they can survive in oxygen and nutrient-poor environments and even withstand treatment. This work was carried out as a continuation of a study aimed towards gaining greater mechanistic understanding of how conditions within the tumour microenvironment impact on both androgen sensitive (LNCaP) and androgen independent (LNCaP-abl and LNCaP-abl-Hof) prostate cancer cell lines. Here we have applied technically robust and reproducible label-free liquid chromatography mass spectrometry analysis for comprehensive proteomic profiling of prostate cancer cell lines under hypoxic conditions. This led to the identification of over 4,000 proteins – one of the largest protein datasets for prostate cancer cell lines established to date. The biological and clinical significance of proteins showing a significant change in expression as result of hypoxic conditions was established. Novel, intuitive workflows were subsequently implemented to enable robust, reproducible and high throughput verification of selected proteins of interest. Overall, these data suggest that this strategy supports identification of protein biomarkers of prostate cancer progression and potential therapeutic targets for CRPC.

show abstract

Section: Discussionmentioning

confidence: 99%

Probing the prostate tumour microenvironment II: Impact of hypoxia on a cell model of prostate cancer progression

Tonry

Armstrong

2017

Oncotarget

View full text Add to dashboard Cite

show abstract

“…Mitoxantrone (Novantrone) is an anticancer drug that inhibits the DNA topoisomerase II activity which results in preventing the DNA synthesis process, and inhibiting cellular proliferation. 109 This drug was approved for the treatment of RRMS, SPMS, and PRMS, where it acts as an immunosuppressant inhibiting immune cells proliferation, their antigen presentation and inflammatory cytokines secretion. 110 A study by Scott et al 111 showed that intravenous treatment of MS patients with mitoxantrone reduced the relapse rate and delayed the progression of the disease.…”

Section: Role Of Mitoxantrone In Modulating Chemokines and Chemokine mentioning

confidence: 99%

<p>Targeting Chemokines and Chemokine Receptors in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis</p>

Dhaiban

Al‐Ani

Elemam

et al. 2020

JIR

View full text Add to dashboard Cite

Multiple sclerosis (MS) is an immune-mediated and neurodegenerative disorder that results in inflammation and demyelination of the central nervous system (CNS). MS symptoms include walking difficulties, visual weakening, as well as learning and memory impairment, thus affecting the quality of the patient's life. Chemokines and chemokine receptors are expressed on the immune cells as well as the CNS resident cells. Several sets of chemokine receptors and their ligands tend to be pathogenic players in MS, including CCL2,

show abstract

“…Mitoxantrone anticancer drug is known to do its anticancer activity via DNA intercalation, inhibition of transferase human CDK2 and inhibition of topoisomerase II [33][34][35][36].…”

Section: Molecular Docking and Binding Energy Calculationsmentioning

confidence: 99%

Theoretical and experimental studies on anticancer drug mitoxantrone

Al‐Otaibi

Wasli

El-Gogary

2018

Journal of Molecular Structure

View full text Add to dashboard Cite

Inhibition of DNA Topoisomerase Type IIα(TOP2A) by Mitoxantrone and Its Halogenated Derivatives: A Combined Density Functional and Molecular Docking Study

Cited by 22 publications

References 63 publications

Probing the prostate tumour microenvironment II: Impact of hypoxia on a cell model of prostate cancer progression

Probing the prostate tumour microenvironment II: Impact of hypoxia on a cell model of prostate cancer progression

<p>Targeting Chemokines and Chemokine Receptors in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis</p>

Theoretical and experimental studies on anticancer drug mitoxantrone

Contact Info

Product

Resources

About